Stocktoria
Damora Therapeutics, Inc. DMRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-29
Damora Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $26.9M | $6.4M | $23.8M | $48.2M | $38.5M |
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M |
| Income tax | $50,000 | $41,000 | $0 | $0 | $0 |
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M |
| EPS (diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 |
| Operating cash flow | -$6.7M | -$18.6M | -$36.9M | -$42.9M | -$52.3M |
| Free cash flow | — | — | — | -$43.1M | -$52.5M |
| Cash & equivalents | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M |
| Total liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M |
| Shareholders' equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M |
Source: SEC EDGAR filings · CIK 0001800315 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.